Status:
Ready to upload
Record number:
1490
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
More than 90% of fatal TRALI directed against HNA-3b or HLA Class II; only 17% of patients transfused with anti-HNA-3a developed mild/moderate and 22% severe pulmonary reactions
Alerting signals, symptoms, evidence of occurrence:
This Perspective proposes two models for TRALI; immune and non-immune. For immune they recommend dividing into three parts: Anti-HLA Class I, anti-HLA ClassII, and anti-HNA.
Demonstration of imputability or root cause:
Literature review
Groups audience:
Keywords:
References:
Suggest new keywords:
antibodies
Reference attachment:
Suggest references:
Warkentin TE, Greinacher A, Bux, J. The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia
Expert comments for publication:
This is a Perspective, i.e. a commentary that proposes a new nomenclature for TRALI